Why it Matters
IRA Watchdog is entering federal lobbying for the first time. The healthcare advocacy organization registered DLA Piper LLP as their lobbying firm for 2025. This marks a new player in drug pricing debates as Trump’s most-favored-nation executive order threatens to reshape pharmaceutical policy.
By the Numbers
- First-time lobbying client: No previous registrations on record
- Lobbying team: Two experienced health policy professionals
- Combined experience: 14+ years in congressional health policy roles
- Firm reach: DLA Piper is one of the world’s largest law firms
Key lobbyists:
- Rachel B. Portman: Former Senate HELP Committee deputy director
- Margaret Coulter Martin: Nine years of Senate health policy experience
Broader Context
Trump signed a sweeping most-favored-nation drug pricing executive order in May 2025. The policy forces pharmaceutical companies to match prices from other countries. Companies have 180 days to comply or face regulatory enforcement. The administration is also considering tariffs up to 250% on pharmaceutical imports.
The Agenda
IRA Watchdog will lobby on “medical and disease research issues.” No specific legislation is identified in their registration. The broad focus suggests engagement across multiple drug pricing initiatives. This includes Medicare negotiation expansion and pharmaceutical transparency measures.
Competitive Landscape
Pharmaceutical trade groups have strongly opposed Trump’s pricing policies. PhRMA and BIO warned the most-favored-nation policy would “devastate” biotech companies. Multiple industry organizations are mobilizing advocacy efforts. IRA Watchdog enters a crowded field of healthcare policy advocates.
Between The Lines
Congress remains active on drug pricing despite the new executive order. The SMART Prices Act would expand Medicare negotiation authority. The DTC Act of 2025 requires price disclosure in drug advertisements.
Recent Senate HELP Committee hearings addressed biosimilar market barriers. House oversight examined IRA’s impact on medicine. Democrats continue pushing for expanded price controls.
The Bottom Line
IRA Watchdog enters lobbying as pharmaceutical policy faces unprecedented disruption. Their HELP Committee-experienced team positions them well for technical debates. The timing suggests they’re responding to immediate industry threats rather than long-term strategic planning.
Spot something wrong? Report an issue with this article